GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Biogen Idec Inc (BIIB) [hlAlert]

Rating:
Hold BIIB

Biogen Idec Inc (BIIB) downgraded to Hold by Standpoint Research

Posted on: Thursday,  Oct 28, 2010  11:25 AM ET by Standpoint Research

Standpoint Research rated Hold Biogen Idec Inc (NASDAQ: BIIB) on 10/28/2010. Previously Standpoint Research rated Buy Biogen
Idec Inc (NASDAQ: BIIB) on 01/19/2010., when the stock price was $54.89. Since then, Biogen Idec Inc has gained 15.30% of its value until Standpoint Research rated BIIB Buy on 10/28/2010, when the price was $63.29. .

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company?s products address diseases such as multiple sclerosis, non-Hodgkin?s lymphoma (NHL), rheumatoid arthritis (RA), crohn?s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

Standpoint Research provides independent equity research that is free from the conflicts of asset management, investment banking, proprietary trading, and fee-for-research arrangements. We provide thorough analysis, diagnostics and forecasts on domestic and international equities and markets backed by alpha-generating variables back-tested on many years of data. Standpoint Research currently advises and sells its research to pension funds, hedge funds and asset management firms. Wall Street analysts have an optimistic bias, while we are more objective. In fact some of the variables in our model that are looked at as positives by Wall Street actually carry negative weight in our model. We have a strict discipline that includes running our proprietary 155-variable valuation and diagnostics model with a personal and subjective overlay that has been proven to add value. The effectiveness is demonstrated through our impressive track record of recommendations.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/7/2016 3:25 PM Buy
None
284.59 360.00
as of 12/31/2010
1 Week   
1 Month   
3 Months up  12.77 %
1 YTD up  15.30 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/28/2010 11:25 AM Hold
None
63.29
1/19/2010 8:25 AM Buy
None
54.89 70.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy